T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction 09/25/25
Welcome to Cardiology Today â Recorded September 25, 2025. This episode summarizes 5 key cardiology studies on topics like aortic stenosis and mortality. Key takeaway: T.A.V.R.: A.T./E.T. Ratio Improves Outcome Prediction.
Article Links:
Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR. (JACC. Cardiovascular interventions)
Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study. (JACC. Cardiovascular interventions)
Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States. (JACC. Cardiovascular interventions)
Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy. (JACC. Cardiovascular interventions)
Article 5: Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry. (JACC. Cardiovascular interventions)
Full episode page: https://podcast.explainheart.com/podcast/t-a-v-r-a-t-e-t-ratio-improves-outcome-prediction-09-25-25/
đ Featured Articles
Article 1: Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992809
Summary: This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.
Article 2: 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992807
Summary: Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.
Article 3: Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992805
Summary: This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.
Article 4: Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992803
Summary: This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-related cardiogenic shock and multivessel disease. The study provides evidence regarding optimal percutaneous coronary intervention strategies in this high-risk population. The results help refine guidelines for percutaneous coronary intervention in patients with S.T.-segment elevation myocardial infarction complicated by cardiogenic shock and multivessel disease.
Article 5: Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry.
Journal: JACC. Cardiovascular interventions
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40992801
Summary: Registry. This study analyzed data from the European Registry of Chronic Total Occlusion to investigate the use of drug-coated balloons in percutaneous coronary intervention for chronic total occlusions. The findings provide insights into the frequency of use, patient and lesion characteristics, and outcomes associated with drug-coated balloon use in chronic total occlusion P.C.I.. The results support the role of drug-coated balloons in chronic total occlusion P.C.I. for limiting stent length and addressing distal vessel disease.
đ Transcript
Today’s date is September 25, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-T.A.V.R.. This study evaluated the acceleration time to ejection time ratio as an alternative hemodynamic measurement to mean gradient for assessing prosthetic valve function after transcatheter aortic valve replacement. The study found that the acceleration time to ejection time ratio may be a more reliable predictor of clinical outcomes post-transcatheter aortic valve replacement compared to mean gradient, potentially reducing the influence of cardiac output and pressure recovery confounders. These findings suggest that acceleration time to ejection time ratio could improve the evaluation of valve performance and risk stratification in patients following transcatheter aortic valve replacement.
Article number two. 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The M.I.S.C.E.N.D. Study. The M.I.S.C.E.N.D. study, a prospective single-arm trial, evaluated the Edwards Eos transcatheter mitral valve replacement system in patients with clinically significant mitral regurgitation at high surgical risk. Results showed that transfemoral transcatheter mitral valve replacement with the Eos system demonstrated acceptable safety and efficacy at one year, offering a potential treatment option for high-risk patients with symptomatic mitral regurgitation. Further research is warranted to compare this approach with other mitral valve interventions.
Article number three. Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States. This study analyzed Medicare claims data to determine trends and outcomes of mitral valve interventions in elderly patients. The study identified utilization trends in mitral valve intervention and factors associated with five-year mortality, offering insights into long-term outcomes for elderly patients undergoing these procedures. These findings help inform clinical decision-making and resource allocation in the management of mitral valve disease in older adults.
Article number four. Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy. This DanGer Shock substudy investigated the association between percutaneous coronary intervention strategy and outcomes in patients with S.T.-segment elevation myocardial infarction-related cardiogenic shock and multivessel disease. The study provides evidence regarding optimal percutaneous coronary intervention strategies in this high-risk population. The results help refine guidelines for percutaneous coronary intervention in patients with S.T.-segment elevation myocardial infarction complicated by cardiogenic shock and multivessel disease.
Article number five. Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The E.R.C.T.O. Registry. This study analyzed data from the European Registry of Chronic Total Occlusion to investigate the use of drug-coated balloons in percutaneous coronary intervention for chronic total occlusions. The findings provide insights into the frequency of use, patient and lesion characteristics, and outcomes associated with drug-coated balloon use in chronic total occlusion P.C.I.. The results support the role of drug-coated balloons in chronic total occlusion P.C.I. for limiting stent length and addressing distal vessel disease.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
aortic stenosis, mortality, mean gradient, mitral valve intervention, S.T.-segment elevation myocardial infarction, DanGer Shock, Eos system, elderly patients, M.I.S.C.E.N.D. study, cardiogenic shock, mitral regurgitation, E.R.C.T.O. registry, acceleration time, transcatheter mitral valve replacement, stent length, drug-coated balloons, Medicare, transfemoral, ejection time, multivessel disease, chronic total occlusion, percutaneous coronary intervention, transcatheter aortic valve replacement.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow